Hims & Hers began selling a compounded oral version of Novo Nordisk’s newly approved Wegovy pill, prompting immediate legal threats from Novo. The telehealth company framed the product as an alternative for patients, while Novo called the move “unapproved” and signaled litigation to protect its intellectual property and branded launch. Attorneys and industry counsel note mixed legal prospects for challenges to compounding and telehealth distribution models; litigation would probe patent, FDA approval and state compounding regulations. Novo’s response underscores how fast-moving weight-loss markets are triggering legal and commercial skirmishes across telehealth and pharma. Stakeholders—from pharmacy compounders to payers—will watch whether regulators or courts set limits on compounder sales of near-identical oral versions of recently approved biologic-derived small molecules. Rapid contestation matters because it could reshape patient access, pricing and competitive tactics in the GLP‑1 obesity market.